Form 4: Envveno Medical Corp Director Acquires Stock Options

Robert Gray, a director at enVVeno Medical Corp, acquired 19,752 stock options on December 18, 2024, which vest quarterly throughout 2025.

Summary

• Robert Gray, a director of enVVeno Medical Corp, was granted 19,752 stock options on December 18, 2024.
• These options were issued under the company's Amended and Restated 2016 Omnibus Incentive Plan.
• The options have an exercise price of $2.57.
• The options vest in equal quarterly installments on the last day of each fiscal quarter during the 2025 calendar year.
• The options expire on December 18, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock option grants to directors, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The grant of stock options to a director aligns their interests with the company's performance.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The stock options will vest in equal quarterly installments throughout 2025.

Industry Context

Stock option grants to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly listed companies.
• The vesting schedule of quarterly installments over a year is a typical approach to encourage long-term commitment.
• The 10-year expiration period is also a common practice for stock options.

Stakeholder Impact

• The stock option grant may positively impact shareholder confidence by aligning director interests with company performance.

Key Dates

Keywords

stock options, director, insider trading, equity, vesting, enVVeno Medical Corp, NVNO